ReviewJournal of translational medicine2025
Lactate dehydrogenase A: a potential new target for tumor drug resistance intervention.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.Oncogene · 2026Review
- Rewiring tumor metabolism: heterogeneity, oncometabolites, and adaptive plasticity.Experimental hematology & oncology · 2026Review
- RACK1 governs a dual metabolic switch in lung adenocarcinoma through c-Src/G6PD and TRIM21/LDHA Axes.Cell death & disease · 2026Article
- Review
- Exploring the prognostic value of the magnesium-immune prognostic score (MIPS) in metastatic non-small cell lung cancer receiving Nivolumab.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Machine learning-based integration identifies lactylation biomarkers for prognosis prediction and tumor microenvironment modulation in bladder cancer.Translational andrology and urology · 2026Article
- Integrated serum proteomics and metabolomics reveal an INR-associated multi-omics signature in hepatocellular carcinoma.Clinical proteomics · 2026Article
- Suppression of Tumor Aggression Through Metabolic Reprogramming via Oxamate Targeting LDHA.International journal of molecular sciences · 2026Review
- FBXO39 promotes LDHA-mediated aerobic glycolysis and colorectal cancer progression by p53 degradation.Journal of translational medicine · 2026Article
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- A Metabolites' Interplay Can Modulate DNA Repair by Homologous Recombination.International journal of molecular sciences · 2026Article
- Risk factors for early mortality (within 6 weeks of diagnosis) in Chinese children with acute leukemia: a single-center retrospective cohort study.Annals of hematology · 2026Article
- Lactic Acid in Tumour Biology.Metabolites · 2026Review
- The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells.Frontiers in immunology · 2026Review
- GSG2 promotes aerobic glycolysis and colorectal cancer progression via the MDM2-p53 axis.American journal of cancer research · 2026Article
- Research progress on protein lactylation in female reproductive disease: molecular mechanisms, functions, and therapeutic implications.Frontiers in pharmacology · 2026Review
- LncRNA LMCD1-AS1 Interacts with PHF8 to Promote Hepatocellular Carcinoma Resistance to Multikinase Inhibitors.International journal of biological sciences · 2026Article
- 2-Hydroxyglutarate in onco-pathway: a metabolic driver of proto-oncogene activation.Frontiers in oncology · 2026Review
- Lactylation-related lncRNAs can forecast prognosis and immune response of lung adenocarcinoma.Discover oncology · 2025Article
- An AI-driven multi-omics framework identifies lactylation-mediated therapeutic targets to overcome drug resistance in ovarian cancer.NPJ precision oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tumor drug resistance is a crucial scientific and technological issue that urgently needs to be addressed in cancer treatment. In recent years, research on Lactate dehydrogenase A (LDHA) in the field of tumor drug resistance has progressively deepened, with breakthrough advancements achieved. Due to their metabolic characteristics, tumors often exhibit abnormal LDHA expression, which meets their growth requirements by promoting glycolysis and lactate production. A series of studies in recent years has revealed that in drug-resistant tumors, LDHA regulates its own expression through molecules such as transcription factors and non-coding RNAs, and regulates tumor drug resistance by influencing the stemness of tumor stem cells, TME, and intrinsic tumor drug resistance. In this paper, we first present timely updates on the expression and regulatory mechanisms of LDHA. Importantly, we systematically expound on the mechanisms through which LDHA is implicated in drug resistance to radiotherapy, chemotherapy, and immunotherapy in tumors, including lung and breast cancers. We also discuss a series of scientific issues that urgently need to be elucidated in future research in this field, aiming to provide more evidence and references for elucidating the mechanisms of LDHA-mediated tumor drug resistance and developing new intervention strategies against tumor drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.